Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens

Sani Kizilbash, K. C. Ward, J. J. Liang, I. Jaiyesimi, J. Lipscomb

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose We conducted a comparative survival analysis between patients with resected pancreatic cancer who received adjuvant treatment with either gemcitabine- or 5-fluorouracil-based chemotherapy and chemoradiation regimens. Patients and methods The Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients with pancreatic cancer diagnosed from 1998 to 2005 who received curative surgery and adjuvant chemotherapy with either 5-fluorouracil or gemcitabine. These groups were subdivided by treatment with radiotherapy. Patients were followed until death, study end-point or a maximum of 5 years after diagnosis. Results Three hundred and fifty-nine patients received 5-fluorouracil and 346 received gemcitabine. Compared with chemoradiation with 5-fluorouracil, outcomes for patients who received chemoradiation with gemcitabine did not differ. Patients who received gemcitabine without radiation had increased hazards (poorly differentiated tumours: HR = 1.50, p = 0.01; moderately differentiated tumours, HR = 1.28, p = 0.11). However, outcomes of patients who received 5-fluorouracil without radiation varied with tumour grade. In moderately differentiated tumours, patients had better outcomes with 5-fluorouracil when compared with chemoradiation with 5-fluorouracil (HR = 0.42, p = 0.02). In poorly differentiated tumours, the opposite was true (HR 2.10, p = 0.09). Conclusion Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation.

Original languageEnglish (US)
Pages (from-to)578-589
Number of pages12
JournalInternational Journal of Clinical Practice
Volume68
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Fluorouracil
Drug Therapy
Survival
Radiation
Neoplasms
Adjuvant Chemotherapy
Survival Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens. / Kizilbash, Sani; Ward, K. C.; Liang, J. J.; Jaiyesimi, I.; Lipscomb, J.

In: International Journal of Clinical Practice, Vol. 68, No. 5, 01.01.2014, p. 578-589.

Research output: Contribution to journalArticle

@article{c6e89d7e03444fabb095f01271e475f5,
title = "Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens",
abstract = "Purpose We conducted a comparative survival analysis between patients with resected pancreatic cancer who received adjuvant treatment with either gemcitabine- or 5-fluorouracil-based chemotherapy and chemoradiation regimens. Patients and methods The Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients with pancreatic cancer diagnosed from 1998 to 2005 who received curative surgery and adjuvant chemotherapy with either 5-fluorouracil or gemcitabine. These groups were subdivided by treatment with radiotherapy. Patients were followed until death, study end-point or a maximum of 5 years after diagnosis. Results Three hundred and fifty-nine patients received 5-fluorouracil and 346 received gemcitabine. Compared with chemoradiation with 5-fluorouracil, outcomes for patients who received chemoradiation with gemcitabine did not differ. Patients who received gemcitabine without radiation had increased hazards (poorly differentiated tumours: HR = 1.50, p = 0.01; moderately differentiated tumours, HR = 1.28, p = 0.11). However, outcomes of patients who received 5-fluorouracil without radiation varied with tumour grade. In moderately differentiated tumours, patients had better outcomes with 5-fluorouracil when compared with chemoradiation with 5-fluorouracil (HR = 0.42, p = 0.02). In poorly differentiated tumours, the opposite was true (HR 2.10, p = 0.09). Conclusion Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation.",
author = "Sani Kizilbash and Ward, {K. C.} and Liang, {J. J.} and I. Jaiyesimi and J. Lipscomb",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/ijcp.12353",
language = "English (US)",
volume = "68",
pages = "578--589",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Survival outcomes in patients with early stage, resected pancreatic cancer - A comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens

AU - Kizilbash, Sani

AU - Ward, K. C.

AU - Liang, J. J.

AU - Jaiyesimi, I.

AU - Lipscomb, J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose We conducted a comparative survival analysis between patients with resected pancreatic cancer who received adjuvant treatment with either gemcitabine- or 5-fluorouracil-based chemotherapy and chemoradiation regimens. Patients and methods The Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients with pancreatic cancer diagnosed from 1998 to 2005 who received curative surgery and adjuvant chemotherapy with either 5-fluorouracil or gemcitabine. These groups were subdivided by treatment with radiotherapy. Patients were followed until death, study end-point or a maximum of 5 years after diagnosis. Results Three hundred and fifty-nine patients received 5-fluorouracil and 346 received gemcitabine. Compared with chemoradiation with 5-fluorouracil, outcomes for patients who received chemoradiation with gemcitabine did not differ. Patients who received gemcitabine without radiation had increased hazards (poorly differentiated tumours: HR = 1.50, p = 0.01; moderately differentiated tumours, HR = 1.28, p = 0.11). However, outcomes of patients who received 5-fluorouracil without radiation varied with tumour grade. In moderately differentiated tumours, patients had better outcomes with 5-fluorouracil when compared with chemoradiation with 5-fluorouracil (HR = 0.42, p = 0.02). In poorly differentiated tumours, the opposite was true (HR 2.10, p = 0.09). Conclusion Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation.

AB - Purpose We conducted a comparative survival analysis between patients with resected pancreatic cancer who received adjuvant treatment with either gemcitabine- or 5-fluorouracil-based chemotherapy and chemoradiation regimens. Patients and methods The Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients with pancreatic cancer diagnosed from 1998 to 2005 who received curative surgery and adjuvant chemotherapy with either 5-fluorouracil or gemcitabine. These groups were subdivided by treatment with radiotherapy. Patients were followed until death, study end-point or a maximum of 5 years after diagnosis. Results Three hundred and fifty-nine patients received 5-fluorouracil and 346 received gemcitabine. Compared with chemoradiation with 5-fluorouracil, outcomes for patients who received chemoradiation with gemcitabine did not differ. Patients who received gemcitabine without radiation had increased hazards (poorly differentiated tumours: HR = 1.50, p = 0.01; moderately differentiated tumours, HR = 1.28, p = 0.11). However, outcomes of patients who received 5-fluorouracil without radiation varied with tumour grade. In moderately differentiated tumours, patients had better outcomes with 5-fluorouracil when compared with chemoradiation with 5-fluorouracil (HR = 0.42, p = 0.02). In poorly differentiated tumours, the opposite was true (HR 2.10, p = 0.09). Conclusion Patients with low-grade resected pancreatic cancer may have better outcomes with 5-fluorouracil-based chemotherapy without radiation when compared with 5-fluorouracil with radiation.

UR - http://www.scopus.com/inward/record.url?scp=84899419316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899419316&partnerID=8YFLogxK

U2 - 10.1111/ijcp.12353

DO - 10.1111/ijcp.12353

M3 - Article

C2 - 24472057

AN - SCOPUS:84899419316

VL - 68

SP - 578

EP - 589

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 5

ER -